Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Disappointing Provenge Sales Stir Doubts About Demand

This article was originally published in The Pink Sheet Daily

Executive Summary

Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.
Advertisement

Related Content

Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition
Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
With Muted Expectations For Provenge, Dendreon Restructures, Cuts Staff
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers
Oncology Price Scale Tips Higher: Seattle Genetics Adcetris To Cost Over $100K
Cell-Therapy Deals A "Strategic Priority" For Shire
Cell Therapy Deals A "Strategic Priority" For Shire
Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price
Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price

Topics

Advertisement
UsernamePublicRestriction

Register

PS072724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel